A Phase 3 interventional study of Semaglutide and Placebo in Non-alcoholic Steatohepatitis, sponsored by Novo Nordisk A/S. Active, not recruiting at 558 sites in 39 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease — 4 open to participants now, 8 under way, 1 of them phase 3. Semaglutide · Non-alcoholic Fatty Liver Disease.
Among the 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease, this one has the largest enrollment, is one of 4 that started in 2021, is the only one in phase 3, and was the 8th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →4 of the 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease are open now, in 3 countries. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18–75
Dr Adnan Agha · Sites in United Arab Emirates
Ages 18–99
RenJi Hospital · Sites in China
Ages 18–65
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 2 · Phase 4 3
First in 2016; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,205 is above the median of 60 across 1,177 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 88 across the 16 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S: 1 open now, 4 under way, 3 of them phase 3. Of 14 finished, 6 (43%) have results posted.
Among the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2021, is one of 3 in phase 3, and was the 8th registered.
Novo Nordisk A/S’s Non-alcoholic Fatty Liver Disease studies by the year they started, since 2016.
3 of the studies testing semaglutide in Non-alcoholic Fatty Liver Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05195944University Health Network, TorontoSemaglutide vs Sitagliptin | 2026-12 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT06005012University of California, San DiegoSemaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease, from their registry updates:
Among Novo Nordisk A/S’s 18 in Non-alcoholic Fatty Liver Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries.
Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance.
Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week.
The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day.
Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Semaglutide administrated subcutaneously once weekly
Drug: Semaglutide
Placebo administrated subcutaneously once weekly
Drug: Placebo
Semaglutide administrated subcutaneously (under the skin) once weekly there will be a period of dose escalation before reaching the target dose.
Placebo administrated subcutaneously (under the skin) once weekly.
Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 72
Part 1: Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 72
Part 2: Cirrhosis-free survival (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 240
Change in body weight
Percentage
Time frame: From randomisation (week 0) to week 72
Resolution of steatohepatitis and improvement in liver fibrosis (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 72
Change in SF-36 (Short Form 36) Bodily Pain
Score points
Time frame: From randomisation (week 0) to week 72
Change in body weight
Percentage
Time frame: From randomisation (week 0) to week 240
Improvement in steatohepatitis with at least a 2-point reduction in NAS and no worsening of fibrosis (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 72
Change in histology-assessed liver collagen proportionate area
Ratio to baseline
Time frame: From randomisation (week 0) to week 72
Worsening in steatohepatitis (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 72
Improvement in histology-assessed ballooning (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 72
Improvement in histology-assessed inflammation (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 72
Improvement in histology-assessed steatosis (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 72
NASH resolution (ballooning of 0, inflammation of 0-1) and above or equal to 2point NAS reduction with no worsening of fibrosis
Count of subject
Time frame: From randomisation (week 0) to week 72
Progression of liver fibrosis in patients with F2 at baseline (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 72
Progression of liver fibrosis
Count of subject
Time frame: From randomisation (week 0) to week 72
Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 240
Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 240
Absence of histological evidence of NASH (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 240
Changes in liver stiffness values assessed by transient elastography (FibroScan®)
Ratio to baseline
Time frame: From randomisation (week 0) to week 72 and week 240
Change in ELF (Enhanced Liver Fibrosis) score
Logarithm
Time frame: From randomisation (week 0) to week 72 and week 240
Change in ALT (alanine aminotransferase)
Ratio to baseline
Time frame: From randomisation (week 0) to week 72 and week 240
Change in AST (aspartate aminotransferase)
Ratio to baseline
Time frame: From randomisation (week 0) to week 72 and week 240
Change in CAP (Controlled Attenuation Parameter) values assessed by transient elastography (FibroScan)
Absolute change
Time frame: From randomisation (week 0) to week 72 and week 240
Change in FAST (FibroScan-AST) score
Probability (absolute change)
Time frame: From randomisation (week 0) to week 72 and week 240
Change in Pro-C3 (pro-peptide of type III collagen)
Logarithm
Time frame: From randomisation (week 0) to week 72 and week 240
Change in inflammation assessed by hsCRP (High Sensitive C-Reactive Protein)
Ratio to baseline
Time frame: From randomisation (week 0) to week 72 and week 240
Change in HbA1c (glycated haemoglobin)
Percentage-points (absolute change)
Time frame: From randomisation (week 0) to week 72 and week 240
Change in triglyceride
Ratio to baseline
Time frame: From randomisation (week 0) to week 72 and week 240
Change in free fatty acids
Ratio to baseline
Time frame: From randomisation (week 0) to week 72 and week 240
Change in LDL (low-density lipoprotein) cholesterol
Ratio to baseline
Time frame: From randomisation (week 0) to week 72 and week 240
Change in HDL (High density lipoprotein ) cholesterol
Ratio to baseline
Time frame: From randomisation (week 0) to week 72 and week 240
Time to first MACE(Major Adverse Cardiovascular event ) (composite endpoint)
Days
Time frame: From randomisation (week 0) to week 240
Major cardio-hepatic event-free survival (Yes/No)
Count of subject
Time frame: From randomisation (week 0) to week 240
Changes in SF-36 (Short Form 36 v2.0 acute ) Physical Component Summary
Score points
Time frame: From randomisation (week 0) to week 72 and week 240
Changes in SF-36 Mental Component Summary
Score points
Time frame: From randomisation (week 0) to week 72 and week 240
Change in SF-36 Bodily Pain
Score points
Time frame: From randomisation (week 0) to week 240
Changes in NASH-CHECK Abdominal Pain
Score points
Time frame: From randomisation (week 0) to week 72 and week 240
Showing the first 100 of 558 sites across 39 countries. Choose a country and city above to see the rest.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Started Apr 2021 (actual). Primary completion is estimated for Apr 2029, 96 months after the start.
Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 96 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
Non-alcoholic Fatty Liver Disease →